Loading
A phase 3 trial of Bacillus Calmette-Guerin: Strain Russian BCG-I in bladder & urothelial cancer, run by Verity Pharmaceuticals Inc., now recruiting.
Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) is a phase 3 interventional study registered as NCT05037279 by Verity Pharmaceuticals Inc., with 540 participants planned, started 2024-04-24 and due to reach its primary completion in 2029-02. Interventions recorded: Bacillus Calmette-Guerin: Strain Russian BCG-I and Bacillus Calmette-Guerin: Strain TICE.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.